Imunon, Inc. - Common Stock IMNN 深 沪
等待开盘 11-07 09:30:00 美东时间
3.96
-0.040
-1.00%
华盛通- 最 高4.05
- 今 开4.05
- 成交量 3.72万股
- 最 低 3.90
- 昨 收 4.00
- 总市值 998.40万
- 52周最高 41.2174
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 3.84
- 委 比 -43.02%
- 总股本 252.12万
- 历史最高 25857.3851
- 量 比 0.48
- 振 幅 3.75%
- 历史最低 3.90
- 每 手 1
- 风险率 4.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多IMUNON To Present Ongoing Phase 3 OVATION 3 Clinical Trial Of IMNN-001 At IGCS 2025 Annual Global Meeting
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025
10-30 20:07
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMUNON, Inc. is advancing its IMNN-001 therapy for advanced ovarian cancer, with new Phase 2 data to be presented at SITC 2025. The IL-12 DNA-based therapy shows improved survival and immune response in trials. The pivotal Phase 3 OVATION 3 trial is ongoing to confirm these results.
10-23 14:01
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMUNON Inc. will host an R&D Day for investors on November 10, 2025, in New York City, to provide updates on its Phase 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. Keynote speakers include ovarian cancer experts, principal investigators, and statistical experts, who will discuss the latest data and progress of the OVATION 3 Study. The event will also feature a live Q&A session and networking opportunities. IMUNON...
10-20 12:05
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
IMUNON, Inc., a clinical-stage biotech company, is seeking strategic partners to advance its PlaCCine technology platform. The company will present IMNN-101, its investigational DNA plasmid vaccine, at two upcoming vaccine conferences, highlighting proof-of-concept clinical trial results. IMNN-101 demonstrated stronger durability of protection and immune response compared to mRNA vaccines, with no serious adverse effects reported. IMUNON aims to ...
10-17 12:10
IMUNON To Present Phase 3 OVATION 3 Clinical Trial IMNN-001 At ESMO Congress
Prestigious European Society for Medical Oncology Conference "trials-in-progress" sessionPivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underwayCompany on track with established
10-14 20:21
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
<p>IMUNON, Inc. announced the acceptance of an abstract on its Phase 3 OVATION 3 trial for IMNN-001, a DNA-mediated IL-12 immunotherapy, for presentation at the European Society for Medical Oncology (ESMO) Congress 2025. IMNN-001, based on TheraPlas® technology, is designed to locally produce IL-12 in the tumor microenvironment, enhancing anti-cancer immunity. The trial is enrolling patients with newly diagnosed advanced ovarian cancer and has sh...
10-14 12:20
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
IMUNON announces positive results from its Phase 2 OVATION 2 Study for IMNN-001, an IL-12 immunotherapy for advanced ovarian cancer. The study highlights significant anti-cancer immune responses, improved overall survival, and a favorable safety profile. A pivotal Phase 3 trial (OVATION 3) is underway, with four trial sites activated and more being added to accelerate patient recruitment.
09-22 12:05
IMUNON To Present New Translational Data From Phase 2 OVATION 2 Study Of IMNN-001 At 2025 AACR Special Conference In Cancer Research
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3
09-19 20:07
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
IMUNON, a clinical-stage biotech company, is advancing its DNA-mediated immunotherapy IMNN-001 in a pivotal Phase 3 trial for treating advanced ovarian cancer. New translational data from the Phase 2 OVATION 2 Study will be presented at the AACR Special Conference. IMNN-001, based on TheraPlas® technology, delivers IL-12 via nanoparticles to activate anti-cancer immunity. Phase 2 results showed significant improvements in overall and progression-...
09-19 12:05
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
IMUNON, a clinical-stage biotechnology company, announced that a pre-recorded presentation will be available online starting September 5, 2025, as part of the H.C. Wainwright Global Investment Conference. The presentation will be accessible via webcast for 90 days. IMUNON’s management will also hold in-person investor meetings from September 8-10. The company focuses on DNA-mediated immunotherapies, including its lead program IMNN-001 for ovarian...
09-02 12:05
